Darnytsia Registers a Modern Antibacterial Medicine in Bosnia and Herzegovina

Darnytsia Pharmaceutical Company is expanding its international presence: a medicine for effective antibacterial therapy has been registered in Bosnia and Herzegovina.

The antibiotic registered in Bosnia and Herzegovina is used for severe forms of pneumonia as well as infections of the skin and soft tissues, providing rapid and effective elimination of pathogenic bacteria in situations where treatment needs to be as effective and safe as possible.

The entry of a Ukrainian medicine into the international market is further proof that our products meet the highest quality standards and can successfully compete on the global arena.

“The spread of our medicines abroad is not just export, it is recognition of Ukrainian quality and the availability of modern pharmacotherapy for patients in Europe. We are constantly working to expand our international presence and are proud that Ukrainian products have earned strong trust beyond Ukraine’s borders,” commented Hurhen Karapetian, Export & Hospital Sales Director at Darnytsia Pharmaceutical Company.

“Behind every international registration stands not only professionalism, but also a great desire to show the world the strength of Ukrainian pharmaceuticals. When our medicines go through strict European regulations, it is yet another confirmation that Ukraine produces products worthy of global standards. This inspires us to keep moving forward and discover new horizons,” adds Anna Pavliuk-Havrylova, Head of International Registration and New Market Entry at Darnytsia Pharmaceutical Company.

It is worth noting that Darnytsia recently registered another medicinal product in Bosnia and Herzegovina — an antimycotic from the group used for systemic therapy and prevention of fungal infections.

Darnytsia continues to expand systematically its presence on international markets: the company’s products are already represented in more than 20 countries worldwide.